受强制性开放获取政策约束的文章 - Paolo Caimi了解详情
无法在其他位置公开访问的文章：4 篇
A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody–drug conjugate, in relapsed/refractory B-cell non-Hodgkin lymphoma
BS Kahl, M Hamadani, J Radford, C Carlo-Stella, P Caimi, E Reid, ...
Clinical Cancer Research 25 (23), 6986-6994, 2019
强制性开放获取政策： National Institute for Health Research, UK
CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
PL Zinzani, C Carlo‐Stella, M Hamadani, AF Herrera, SM Ansell, ...
Hematological Oncology 39, 2021
强制性开放获取政策： National Health and Medical Research Council, Australia
Diffuse large B cell lymphoma in patients 80 years and older: worse survival after treatment without increased relapse rates
M Keenan, A Diamond, K Boughan, B Cooper, M Gallogly, E Malek, ...
Clinical Lymphoma Myeloma and Leukemia 21 (11), 799-804, 2021
强制性开放获取政策： US National Institutes of Health
Evaluation of ctDNA in a phase I/II trial in relapsed or refractory large B‐cell lymphoma of epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T‐cell–engaging antibody.
D Soong, C Thieblemont, J Karavitis, B Hess, P Caimi, T Feldman, ...
Hematological Oncology 41, 2023
强制性开放获取政策： German Research Foundation
可在其他位置公开访问的文章：66 篇
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
强制性开放获取政策： US National Institutes of Health, Fonds de recherche du Québec - Santé
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ...
Annals of oncology 32 (6), 787-800, 2021
强制性开放获取政策： US National Institutes of Health, Fonds de recherche du Québec - Santé
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC …
K Dunleavy, MA Fanale, JS Abramson, A Noy, PF Caimi, S Pittaluga, ...
The Lancet Haematology 5 (12), e609-e617, 2018
强制性开放获取政策： US National Institutes of Health
Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19
MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ...
JAMA oncology 7 (8), 1167-1175, 2021
强制性开放获取政策： US National Institutes of Health, US Assistant Secretary for Preparedness …
The molecular analysis for therapy choice (NCI-MATCH) trial: lessons for genomic trial design
KT Flaherty, R Gray, A Chen, S Li, D Patton, SR Hamilton, PM Williams, ...
JNCI: Journal of the National Cancer Institute 112 (10), 1021-1029, 2020
强制性开放获取政策： US National Institutes of Health
Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma
NH Fowler, F Samaniego, W Jurczak, N Ghosh, E Derenzini, JA Reeves, ...
Journal of Clinical Oncology 39 (15), 1609-1618, 2021
强制性开放获取政策： UK Medical Research Council, Wellcome Trust
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers
AM Evens, A Danilov, D Jagadeesh, A Sperling, SH Kim, R Vaca, C Wei, ...
Blood, The Journal of the American Society of Hematology 137 (3), 374-386, 2021
强制性开放获取政策： US National Institutes of Health
Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era
JN Gerson, E Handorf, D Villa, AS Gerrie, P Chapani, S Li, LJ Medeiros, ...
Journal of Clinical Oncology 37 (6), 471-480, 2019
强制性开放获取政策： US National Institutes of Health
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
GI Shapiro, P LoRusso, A Dowlati, K T. Do, CA Jacobson, ...
British journal of cancer 124 (4), 744-753, 2021
强制性开放获取政策： US National Institutes of Health
Automated manufacture of autologous CD19 CAR-T cells for treatment of non-Hodgkin lymphoma
Z Jackson, A Roe, AA Sharma, FBTP Lopes, A Talla, S Kleinsorge-Block, ...
Frontiers in immunology 11, 1941, 2020
强制性开放获取政策： US National Institutes of Health
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
VM Orellana-Noia, DR Reed, AA McCook, JM Sen, CM Barlow, ...
Blood, The Journal of the American Society of Hematology 139 (3), 413-423, 2022
强制性开放获取政策： US National Institutes of Health
Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia
MW Harr, PF Caimi, KS McColl, F Zhong, SN Patel, PM Barr, ...
Cell Death & Differentiation 17 (9), 1381-1391, 2010
强制性开放获取政策： US National Institutes of Health
Emerging therapeutic approaches for multipotent mesenchymal stromal cells
PF Caimi, J Reese, Z Lee, HM Lazarus
Current opinion in hematology 17 (6), 505-513, 2010
强制性开放获取政策： US National Institutes of Health
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
M Hamadani, GP Collins, PF Caimi, F Samaniego, A Spira, A Davies, ...
The Lancet Haematology 8 (6), e433-e445, 2021
强制性开放获取政策： US National Institutes of Health, Cancer Research UK
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
AM Evens, KR Carson, J Kolesar, C Nabhan, I Helenowski, N Islam, ...
Annals of oncology 24 (12), 3076-3081, 2013
强制性开放获取政策： US National Institutes of Health
A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers
DP Wong, NK Roy, K Zhang, A Anukanth, A Asthana, NJ Shirkey-Son, ...
Nature communications 13 (1), 217, 2022
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定